Prostate Cancer Death Linked With Shorter Sleep Duration

Video

This video examines results of a study that found that shorter sleep duration was linked with an increased risk of death among patients with prostate cancer.

In this video, Susan M. Gapstur, PhD, MPH, of the American Cancer Society in Atlanta, discusses an analysis of two large, long-term cohort studies-Cancer Prevention Study-I and Cancer Prevention Study-II-that found that sleep duration was linked with an increased risk of death among patients with prostate cancer.

Results of the study were presented at the 2017 American Association for Cancer Research (AACR) Annual Meeting, held April 1–5 in Washington, DC.

The biological mechanism behind this association is unclear, but research has shown that lack of sleep and the presence of light at night can affect melatonin production, and that low melatonin production can lead to an increase in genetic mutations and can limit DNA repair.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
“If you have a [patient in the] fourth or fifth line, [JNJ-5322] could be a valid drug of choice,” said Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD.
Earlier treatment with daratumumab may be better tolerated for patients with pretreated MRD-negative multiple myeloma.
The trispecific antibody JNJ-5322 demonstrated superior efficacy vs approved agents in multiple myeloma in results shared at the 2025 EHA Congress.
Despite CD19 CAR T-cell therapy exhibiting efficacy in patients with relapsed/refractory large B-cell lymphoma, less than half achieve long-term remission.
Current findings from the phase 1/2 CaDAnCe-101 trial show no predictive factors of improved responses with BGB-16673 in patients with CLL or SLL.
The phase 3 NIVOSTOP trial evaluated an anti–PD-1 immunotherapy, nivolumab, in a patient population similar in the KEYNOTE-689 trial.
Related Content